S'abonner

Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less - 12/10/17

Doi : 10.1016/S0022-3476(96)70356-6 
Alvaro Gonzalez, MDa, Ilene R.S. Sosenko, MD, Jay Chandar, MD, Helmut Hummler, MD, Nelson Claure, MS, Eduardo Bancalari, MD

Partially supported by University of Miami Project: New Born, and by a National Institutes of Health-Biomedical Research Support Grant Shared Instrumentation Grant, “Ultrasonographic Imaging System With Color-Flow Doppler” (grant No. 1 S10 RR06523-01).


Abstract

OBJECTIVE: To test the hypotheses that (1) infection increases ductal dilatory prostaglandins and inflammatory mediators that may influence the closure of a patent ductus arteriosus (PDA), increasing the incidence of late episodes of PDA (after 7 days) and the rate of closure failures, and (2) the concurrence of PDA and infection increases the risk of chronic lung disease (CLD). METHODS: One hundred fourteen premature infants (birth weight, 500 to 1000 gm) were prospectively assessed for PDA and infection. Serum levels of 6-ketoprostaglandin F1⍺ and tumor necrosis factor alpha were measured routinely in all infants and when PDA or infection was present. Multivariate assessment of risk factors for PDA closure failure and for CLD was done by logistic regression, and expressed as an odds ratio and as 95% confidence intervals. RESULTS: Late PDA episodes were more frequent in infants with infection than in those without infection. A temporally related infection (<5 days between both diagnoses) was associated with an increased risk of PDA closure failure (odds ratio, 19.1 [confidence interval, 4 to 90]). In addition to birth weight and the severity of initial respiratory failure, PDA and infection increased the risk of CLD (odds ratio, 11.7 [confidence interval, 1.7 to 81] for PDA; odds ratio, 3.1 [confidence interval, 1 to 11] for infection). Furthermore, when both factors were temporally related, they further increased the risk of CLD (odds ratio, 29.6 [confidence interval, 4.5 to >100]). Infants with infection and those with PDA had higher levels of 6-ketoprostaglandin F1⍺ than did control subjects. Levels of tumor necrosis factor alpha were also elevated in infants with infection and in those with late PDA. CONCLUSIONS: Infection adversely influences PDA outcome by increasing the risk of late ductal reopening and PDA closure failures. Increased levels of prostaglandins and tumor necrosis factor alpha in infants with infection may explain the poor PDA outcome. The concurrence of PDA and infection potentiates their negative effects on the risk of CLD. (J PEDIATR 1996;128:470-8)

Le texte complet de cet article est disponible en PDF.

Abbreviations : CLD, 6-keto-PGF1⍺, PDA, RDS, TNF⍺


Plan


 From the Department of Pediatrics, Divisions of Neonatology and Pediatric Cardiology, University of Miami School of Medicine, Miami, Florida
 aPresently at the Catholic University of Chile, Santiago.
 Reprint requests: Eduardo Bancalari, MD, Department of Pediatrics (R131), Division of Neonatology, PO Box 016960, Miami, FL 33101.
 0022-3476/96/$5.00 + 0 9/20/71604


© 1996  Mosby, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 128 - N° 4

P. 470-478 - avril 1996 Retour au numéro
Article précédent Article précédent
  • Increase in the concentration of transforming growth factor beta-1 in bronchoalveolar lavage fluid before development of chronic lung disease of prematurity
  • S. Kotecha, A. Wangoo, M. Silverman, R.J. Shaw
| Article suivant Article suivant
  • Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction
  • Asher Tal, Haim Golan, Nissan Grauer, Micha Aviram, David Albin, Michael R. Quastel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.